MX2015003535A - Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa. - Google Patents

Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa.

Info

Publication number
MX2015003535A
MX2015003535A MX2015003535A MX2015003535A MX2015003535A MX 2015003535 A MX2015003535 A MX 2015003535A MX 2015003535 A MX2015003535 A MX 2015003535A MX 2015003535 A MX2015003535 A MX 2015003535A MX 2015003535 A MX2015003535 A MX 2015003535A
Authority
MX
Mexico
Prior art keywords
compounds
dihydropyrrolidino
pyrimidines
kinase inhibitors
present
Prior art date
Application number
MX2015003535A
Other languages
English (en)
Spanish (es)
Inventor
Cynthia Shafer
Huw Tanner
Michael Patrick Dillon
Mika Lindvall
Daniel Poon
Savithri Ramurthy
Vivek Rauniyar
Sharadha Subramanian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2015003535A publication Critical patent/MX2015003535A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2015003535A 2012-09-19 2013-09-17 Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa. MX2015003535A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261702981P 2012-09-19 2012-09-19
PCT/US2013/060032 WO2014047020A1 (en) 2012-09-19 2013-09-17 Dihydropyrrolidino-pyrimidines as kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2015003535A true MX2015003535A (es) 2015-07-14

Family

ID=49274870

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003535A MX2015003535A (es) 2012-09-19 2013-09-17 Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa.

Country Status (13)

Country Link
US (1) US9546173B2 (https=)
EP (1) EP2897961B1 (https=)
JP (1) JP6186440B2 (https=)
KR (1) KR20150056550A (https=)
CN (1) CN104640865B (https=)
AU (1) AU2013318283A1 (https=)
BR (1) BR112015005982A2 (https=)
CA (1) CA2882410A1 (https=)
EA (1) EA201590600A1 (https=)
ES (1) ES2612885T3 (https=)
IN (1) IN2015DN01328A (https=)
MX (1) MX2015003535A (https=)
WO (1) WO2014047020A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2612885T3 (es) * 2012-09-19 2017-05-19 Novartis Ag Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa
JP7349491B2 (ja) * 2018-07-12 2023-09-22 ユーシービー バイオファルマ エスアールエル Il-17モジュレーターとしてのスピロ環状インダン類似体
WO2020243457A1 (en) * 2019-05-29 2020-12-03 Viogen Biosciences, Llc Compounds and therapeutic uses thereof
CN120247783A (zh) * 2019-08-01 2025-07-04 普拉特戈公司 晚期糖基化终产物的抑制剂
PH12022551118A1 (en) * 2019-12-10 2023-09-18 Hoffmann La Roche New braf inhibitors as paradox breakers
PL4073065T3 (pl) 2019-12-10 2025-05-19 F. Hoffmann-La Roche Ag Nowe pochodne metylochinazolinonu
WO2021218912A1 (zh) 2020-04-30 2021-11-04 南京明德新药研发有限公司 含苯基并内磺酰胺的化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7208498B2 (en) * 2002-07-15 2007-04-24 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
CA2547080A1 (en) * 2003-12-02 2005-07-28 Vertex Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors and uses thereof
PE20060426A1 (es) 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
AU2005323797B2 (en) 2005-01-10 2009-07-09 Pfizer Inc. Pyrrolopyrazoles, potent kinase inhibitors
HRP20110892T1 (hr) 2005-12-13 2011-12-31 Schering Corporation Policiklični derivati indazola koji su inhibitori erk
AR068046A1 (es) 2007-06-05 2009-11-04 Schering Corp Derivados policiclicos de indazol y su uso como inhibidores de erk para el tratamiento del cancer
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) * 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
KR20130121122A (ko) 2010-11-17 2013-11-05 에프. 호프만-라 로슈 아게 종양의 치료 방법
CN103635472B (zh) 2011-02-28 2018-01-12 阵列生物制药公司 丝氨酸/苏氨酸激酶抑制剂
ES2620612T3 (es) * 2012-03-02 2017-06-29 Genentech, Inc. Derivados de sulfóxidos y sulfonas de piridinilo y pirimidinilo
ES2612885T3 (es) * 2012-09-19 2017-05-19 Novartis Ag Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa

Also Published As

Publication number Publication date
IN2015DN01328A (https=) 2015-07-03
CN104640865B (zh) 2018-05-11
US9546173B2 (en) 2017-01-17
EA201590600A1 (ru) 2015-07-30
CN104640865A (zh) 2015-05-20
ES2612885T3 (es) 2017-05-19
EP2897961A1 (en) 2015-07-29
AU2013318283A1 (en) 2015-03-05
BR112015005982A2 (pt) 2017-07-04
JP2015529248A (ja) 2015-10-05
CA2882410A1 (en) 2014-03-27
JP6186440B2 (ja) 2017-08-23
WO2014047020A1 (en) 2014-03-27
KR20150056550A (ko) 2015-05-26
US20150274733A1 (en) 2015-10-01
EP2897961B1 (en) 2016-10-26

Similar Documents

Publication Publication Date Title
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
JO3366B1 (ar) مثبطات بيرازوليل كوينوكزالين كاينيز
PH12017502141A1 (en) Compounds and their methods of use
CA2871471C (en) Dna-pk inhibitors
JO3452B1 (ar) بنزاميدات أمينو اريل مغاير كمثبطات كيناز
EA033343B1 (ru) Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
UA111386C2 (uk) Піридопіразини, які мають протиракову активність через інгібування fgfr-кіназ
MX2015003535A (es) Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa.
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
PH12018502376A1 (en) Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
WO2014138616A3 (en) Pyrazole compounds and methods of use thereof
GB201111427D0 (en) Novel bisindolylmaleimides, pan-pkc inhibitors
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази
MY192305A (en) Bipyrazole derivatives as jak inhibitors
MX2011003390A (es) Compuestos y composiciones útiles en el tratamiento de enfermedades cardiacas con efectos secundarios reducidos.